Поиск по репозиторию
Статья
tocilizumab in the treatment of systemic inflammatory response in a patient with CoVID-19 (clinical case) [тоцилизумаб в лечеНии СиСтемНой воСПалительНой реакции у ПациеНта С COVID-19 (клиНичеСкий Случай)]
2021
Improving the approaches to treating COVID-19 infection opens up the possibility for using previously known groups of drugs that demonstrate their effectiveness in the pathogenetic treatment of this disease. Significant clinical experience in the field of treatment of COVID-19 have been accumulated in Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia. The case study demonstrates the timeliness and effectiveness of anticytokine therapy with COVID-19, the possibility of using a recombinant humanized monoclonal antibody to the human receptor for interleukin-6 (IL-6) (tocilizumab). © 2020 Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR). All rights reserved.
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2021-04-27
Метаданные
Название журнала
- Jurnal Infektologii
Том
- 12
Выпуск
- 3
Страницы
- 90-93
Ключевые слова
- tocilizumab; Article; case report; clinical article; coronavirus disease 2019; drug efficacy; human; systemic inflammatory response syndrome
Издатель
- Interregional public organization Association of infectious disease specialists of Saint-Petersburg and Leningrad region (IPO AIDSSPbR)
Тип документа
- journal article
Тип лицензии Creative Commons
- CC
Правовой статус документа
- Свободная лицензия
Источник
- scopus
